Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel

ABSTRACT The 7-valent and the 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) were introduced to the Israeli National Immunization plan in July 2009 and November 2010, respectively. Our aim was to assess pneumococcal conjugate vaccines (PCVs) uptake and dynamics in serotype-specific pneumococcal nasopharyngeal (NP) carriage in children <5 years old in southern Israel, during the immediate 5 y following PCV introduction. This was an ongoing, prospective, population-based, active surveillance, from July 2009 through December 2014. PCVs uptake and NP cultures were obtained daily from children seen at the Pediatric Emergency Room for any reason. Overall, 10,702 vaccine status and 7,610 NP swabs were obtained. Both PCV7 and PCV13 uptake were high, reaching ˜90% by July 2012 and December 2013, respectively. All-pneumococcal carriage rates significantly declined by 10%, from 54.3% in the early-PCV7 period, to 49.1% in the PCV13 impact period. The respective declines for PCV7, 6A and additional PCV13 serotypes carriage rates were 76%, 90% and 66%. In contrast, non-PCV13 serotypes carriage rates increased significantly throughout the study by 71%. All-pneumococcal carriage rates in children <12 months old decreased significantly by 15%, with similar trends observed in other age groups. Initially, all-pneumococcal carriage rates were 45.7%, and 61.9% in Jewish and Bedouin children, respectively (P < 0.001), with a significant 17% reduction throughout the study observed only in Bedouins. While early carriage rates were higher in unvaccinated children compared to vaccinated children, PCV impact on carriage were similar in both groups. In conclusion, a relatively moderate decline in pneumococcal carriage rates, facilitated by a substantial decrease of vaccine-serotypes and increase of non-vaccine serotypes was observed in the immediate period following PCVs introduction in southern Israel.

[1]  Ankita P. Desai,et al.  Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia , 2015, The Pediatric infectious disease journal.

[2]  C. Whitney,et al.  Use of Pneumococcal Disease Epidemiology to Set Policy and Prevent Disease during 20 Years of the Emerging Infections Program , 2015, Emerging infectious diseases.

[3]  C. Bottomley,et al.  Pneumococcal carriage in rural Gambia prior to the introduction of pneumococcal conjugate vaccine: a population‐based survey , 2015, Tropical medicine & international health : TM & IH.

[4]  K. Rascati,et al.  Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey. , 2015, Clinical therapeutics.

[5]  Á. Gentile.  [Effects of vaccination on invasive pneumococcal disease in South Africa]. , 2015, Archivos argentinos de pediatria.

[6]  D. Greenberg,et al.  Seasonality of both bacteremic and nonbacteremic pneumonia coincides with viral lower respiratory tract infections in early childhood, in contrast to nonpneumonia invasive pneumococcal disease, in the pre-pneumococcal conjugate vaccine era. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Greenberg,et al.  Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. , 2015, The Journal of infectious diseases.

[8]  G. Rahav,et al.  Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. , 2015, Vaccine.

[9]  D. Greenberg,et al.  Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Lindstrand,et al.  Sinusitis and Pneumonia Hospitalization After Introduction of Pneumococcal Conjugate Vaccine , 2014, Pediatrics.

[11]  A. Berglund,et al.  All-Cause Pneumonia Hospitalizations in Children <2 Years Old in Sweden, 1998 to 2012: Impact of Pneumococcal Conjugate Vaccine Introduction , 2014, PloS one.

[12]  C. Whitney,et al.  Declines in Pneumonia Hospitalizations of Children Aged <2 Years Associated with the Use of Pneumococcal Conjugate Vaccines — Tennessee, 1998–2012 , 2014, MMWR. Morbidity and mortality weekly report.

[13]  F. Martinón-Torres,et al.  Evolving Role of 13-valent Pneumococcal Conjugate Vaccine in Clinical Practice , 2014, The Pediatric infectious disease journal.

[14]  N. Andrews,et al.  Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. , 2014, Vaccine.

[15]  D. Greenberg,et al.  Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. , 2014, Vaccine.

[16]  A. Tanskanen,et al.  Colonisation endpoints in Streptococcus pneumoniae vaccine trials. , 2013, Vaccine.

[17]  K. O'Brien,et al.  Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. , 2013, Vaccine.

[18]  K. O'Brien,et al.  Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization , 2013, The Pediatric infectious disease journal.

[19]  S. Madhi,et al.  Temporal Changes in Pneumococcal Colonization in a Rural African Community With High HIV Prevalence Following Routine Infant Pneumococcal Immunization , 2013, The Pediatric infectious disease journal.

[20]  D. Greenberg,et al.  Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  T. Cherian,et al.  Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites , 2013, PLoS medicine.

[22]  C. Whitney,et al.  U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. , 2013, The New England journal of medicine.

[23]  D. Greenberg,et al.  Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. , 2012, Vaccine.

[24]  M. Gilmour,et al.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. , 2012, Canadian journal of microbiology.

[25]  D. Greenberg,et al.  The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. , 2012, Vaccine.

[26]  K. O'Brien,et al.  The fundamental link between pneumococcal carriage and disease , 2012, Expert review of vaccines.

[27]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[28]  C. Chiu,et al.  Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine. , 2011, Vaccine.

[29]  S. Clarke,et al.  Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. , 2011, Vaccine.

[30]  D. Greenberg,et al.  Nasopharyngeal Carriage of Individual Streptococcus pneumoniae Serotypes During Pediatric Pneumonia as a Means to Estimate Serotype Disease Potential , 2011, The Pediatric infectious disease journal.

[31]  P. Morris,et al.  Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease , 2010, BMC infectious diseases.

[32]  D. Greenberg,et al.  [Community acquired pneumonia (CAP) in children younger than 5 years of age in southern Israel]. , 2010, Harefuah.

[33]  R. Dagan,et al.  Increasing Importance of Multidrug-Resistant Serotype 6A Streptococcus pneumoniae Clones in Acute Otitis Media in Southern Israel , 2010, The Pediatric infectious disease journal.

[34]  G. Syrogiannopoulos,et al.  Impact of Heptavalent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of Penicillin-Resistant Streptococcus pneumoniae Among Day-Care Center Attendees in Central Greece , 2008, The Pediatric infectious disease journal.

[35]  O. Vanderkooi,et al.  Effects of Routine Infant Vaccination With the 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Streptococcus pneumoniae in Children in Calgary, Canada , 2008, The Pediatric infectious disease journal.

[36]  R. Cohen,et al.  Impact of Pneumococcal Conjugate Vaccine and of Reduction of Antibiotic Use on Nasopharyngeal Carriage of Nonsusceptible Pneumococci in Children With Acute Otitis Media , 2006, The Pediatric infectious disease journal.

[37]  D. Greenberg,et al.  The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  M. Lipsitch,et al.  Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. , 2005, The Journal of infectious diseases.

[39]  A. Schuchat,et al.  Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. , 2004, The Journal of infectious diseases.

[40]  R. Dagan,et al.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers , 2003, The Pediatric infectious disease journal.

[41]  R. Dagan,et al.  Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. , 2002, The Journal of infectious diseases.